{"id":21992,"date":"2026-03-02T14:06:56","date_gmt":"2026-03-02T14:06:56","guid":{"rendered":"https:\/\/readtrends.com\/en\/universal-flu-weak-spots\/"},"modified":"2026-03-02T14:06:56","modified_gmt":"2026-03-02T14:06:56","slug":"universal-flu-weak-spots","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/universal-flu-weak-spots\/","title":{"rendered":"Universal flu vaccine: How scientists are closing in on the viruses &#8216;weak spots&#8217; &#8211; BBC"},"content":{"rendered":"<article>\n<p><strong>Lead<\/strong><\/p>\n<p>Researchers worldwide are pursuing vaccines that protect against many influenza strains, not just one season&#8217;s variants. Each year roughly 1 billion people become infected and between 290,000 and 650,000 die from influenza-related causes, driving urgency for longer\u2011lasting, broader protection. Teams at institutions including Duke, Mount Sinai and Stanford report promising laboratory and early clinical results as they target conserved parts of the virus. While progress is real, experts caution a truly universal shot remains a difficult, multi-year goal.<\/p>\n<h2>Key takeaways<\/h2>\n<ul>\n<li>Global burden: About 1 billion influenza infections occur annually, with 290,000\u2013650,000 deaths in a typical year.<\/li>\n<li>Seasonal vaccine limits: Standard shots average up to roughly 60% effectiveness and can fall much lower in mismatched seasons.<\/li>\n<li>Candidate pipeline: Around a dozen next\u2011generation or \u2018\u2018universal\u2019\u2019 vaccine candidates are in clinical trials, with many more in preclinical work.<\/li>\n<li>Conserved targets: Scientists are focusing on invariant viral regions such as the haemagglutinin (HA) stem and neuraminidase to broaden protection.<\/li>\n<li>Novel approaches: Strategies include chimeric HA designs, massively multiplexed HA displays, T\u2011cell\u2013focused vaccines and intranasal immune stimulants that protected mice for three months in one study (Feb 2026).<\/li>\n<li>Prediction improvements: AI models have been proposed to complement WHO strain selection processes and may improve seasonal match decisions (2025 research).<\/li>\n<li>Timeline: Some researchers expect substantially improved influenza vaccines within five to ten years, but timelines are uncertain.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>Influenza is not a single pathogen but a family of viruses that circulate in humans, birds and other mammals. Surface proteins haemagglutinin (HA) and neuraminidase (NA) define subtypes (for example H1N1, H3N2), and there are 18 HA and 11 NA varieties that can recombine and mutate. These antigenic changes\u2014seasonal antigenic drift and occasional major shifts\u2014mean immune protection from prior infection or vaccination can rapidly become outdated.<\/p>\n<p>Public health agencies make seasonal vaccine recommendations months before each hemisphere&#8217;s flu season: WHO convenes experts in February for the Northern Hemisphere and again in September for the Southern Hemisphere. Those forecasts draw on global surveillance but are necessarily predictive; unexpected variants can emerge after recommendations are set, as occurred in the 2025\u20132026 season with the rise of H3N2 subclade K.<\/p>\n<p>The practical consequence is that manufacturers and health authorities must repeatedly reformulate and distribute vaccines, and some groups\u2014older adults in particular\u2014get extra\u2011potent formulations. The recurring need to update vaccines has prompted efforts to find viral components that change little over time or to prime immune responses that recognise a wide swath of viral diversity.<\/p>\n<h2>Main event<\/h2>\n<p>One prominent line of work targets the HA stem, a part of the HA molecule that is more conserved than the variable head. Researchers led by Florian Krammer at the Icahn School of Medicine design chimeric HA constructs that present unfamiliar head regions while keeping the same stem, steering the immune response toward the conserved stem. Early human data published in 2020 showed broadly reactive antibodies, and further human trials are planned.<\/p>\n<p>Nicholas Heaton&#8217;s group at Duke is pursuing an alternative: exposing the immune system to very large arrays of HA variants\u2014reportedly tens of thousands\u2014to focus immune attention on the common elements. Heaton&#8217;s 2024 report described promising preclinical results, though human trials have not yet begun. The logic is to overwhelm the immune system&#8217;s tendency to chase variable head epitopes so it instead recognises the invariant portions.<\/p>\n<p>In February 2026, a Stanford team reported a nasal spray that activated lung macrophages in mice, providing broad short\u2011term protection against diverse respiratory pathogens and reducing pathogen loads by 100\u2011 to 1,000\u2011fold; the effect lasted about three months in that model. That approach aims to boost local innate immunity at the airway portal of entry but awaits human testing.<\/p>\n<p>Other projects are emphasizing NA as a target, seeking stronger T\u2011cell responses that detect infected cells regardless of surface variation, or testing novel delivery formats such as intranasal vaccines to block infection at the mucosal surface. Across these programs the shared objective is a vaccine less dependent on precise strain matching.<\/p>\n<h2>Analysis &#038; implications<\/h2>\n<p>Scientific feasibility has strengthened: multiple independent strategies have produced broadly reactive immune responses in animals and early clinical stages. Targeting the HA stem, NA, or T cells each address parts of the virus that evolve more slowly, reducing the chance of immune escape. If any of these approaches scale to humans with durable protection, it would lower annual morbidity and mortality and reduce the public\u2011health burden of yearly reformulation and mass vaccination programs.<\/p>\n<p>However, biological and logistical challenges remain. Conserved sites can be less immunogenic than variable heads, requiring novel antigen design or adjuvants to generate strong, long\u2011lived responses. Safety and efficacy in diverse human populations must be demonstrated across age groups and risk categories. Manufacturing complexity and regulatory pathways for fundamentally new vaccine designs could slow deployment even after efficacy is proven.<\/p>\n<p>Economics and policy will matter as much as science. Sustained investment is needed to carry promising candidates through large, expensive phase 3 trials and to build manufacturing capacity. Public appetite and political will for long\u2011term funding are uncertain; some researchers argue that the term \u201cuniversal\u201d can overpromise and that describing outcomes as \u2018\u2018broadly protective\u2019\u2019 is more realistic and actionable.<\/p>\n<h2>Comparison &#038; data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Measure<\/th>\n<th>Estimate \/ Example<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Annual infections<\/td>\n<td>~1,000,000,000 people<\/td>\n<\/tr>\n<tr>\n<td>Annual deaths (typical year)<\/td>\n<td>290,000\u2013650,000<\/td>\n<\/tr>\n<tr>\n<td>Typical seasonal vaccine effectiveness<\/td>\n<td>Up to ~60% (can be much lower when mismatched)<\/td>\n<\/tr>\n<tr>\n<td>Next\u2011gen candidates in clinical trials<\/td>\n<td>About a dozen<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>These figures highlight why researchers seek broader, longer\u2011lasting protection: even a moderately improved vaccine efficacy across seasons would prevent many illnesses and deaths and decrease the need for frequent reformulation. The table condenses global burden estimates and the current scope of vaccine candidates; however, individual candidate performance varies widely by mechanism and stage of testing.<\/p>\n<h2>Reactions &#038; quotes<\/h2>\n<blockquote>\n<p>&#8220;There are a few weak spots that the virus has,&#8221;<\/p>\n<p><cite>Florian Krammer, Icahn School of Medicine<\/cite><\/p><\/blockquote>\n<p>Krammer summarises the strategy behind several universal vaccine designs: find conserved viral features and train immunity to them. His group has advanced chimeric HA immunogens that bias antibody responses to the HA stem.<\/p>\n<blockquote>\n<p>&#8220;I hate this term [universal],&#8221;<\/p>\n<p><cite>Nicholas Heaton, Duke University<\/cite><\/p><\/blockquote>\n<p>Heaton warns that &#8216;universal&#8217; can raise expectations beyond what current candidates can deliver; he prefers describing outcomes as broadly protective and emphasizes incremental progress over a sudden breakthrough.<\/p>\n<blockquote>\n<p>&#8220;AI systems can augment strain selection and may improve seasonal match decisions,&#8221;<\/p>\n<p><cite>Regina Barzilay, MIT (AI and health researcher)<\/cite><\/p><\/blockquote>\n<p>Barzilay&#8217;s 2025 work suggests machine learning could be integrated with WHO surveillance to sharpen vaccine strain predictions, complementing\u2014but not replacing\u2014expert judgment.<\/p>\n<aside>\n<details>\n<summary>Explainer: How a vaccine can be &#8216;broad&#8217;<\/summary>\n<p>A broadly protective influenza vaccine either directs antibodies to viral parts that change little across strains (for example, the HA stem or NA) or elicits strong cellular immunity (T cells) that recognises conserved internal proteins. Chimeric HA designs swap variable heads onto a constant stem to focus antibodies on the stem. Massive antigen displays present many variants at once to shift immune attention toward shared elements. Intranasal approaches aim to stimulate mucosal and innate defenses at the respiratory entry point. Each method balances immunogenicity, durability and manufacturability in different ways.<\/p>\n<\/details>\n<\/aside>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>Whether any current candidate will deliver lifelong single\u2011dose protection remains unproven; clinical data are not yet available to support that outcome.<\/li>\n<li>The Stanford nasal spray results are limited to mice; human safety and efficacy have not been demonstrated.<\/li>\n<li>Predictions that an improved, broadly protective vaccine will be widely available in five to ten years are informed estimates, not guaranteed timelines.<\/li>\n<\/ul>\n<h2>Bottom line<\/h2>\n<p>Multiple scientific paths toward broader influenza protection are converging: antigen design that exposes conserved viral elements, strategies to harness T cells, and methods to boost mucosal immunity. Early data in animals and preliminary human studies are encouraging, and about a dozen candidates have advanced into clinical testing.<\/p>\n<p>Realising a durable, widely effective vaccine will require continued scientific validation, large human trials, manufacturing scale\u2011up and stable funding. In the meantime, incremental improvements\u2014better seasonal match through AI, higher\u2011dose formulations for older adults and novel delivery routes\u2014can reduce illness and death while the field pursues longer\u2011term goals.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.bbc.com\/future\/article\/20260227-why-is-there-no-universal-flu-vaccine\" target=\"_blank\" rel=\"noopener\">BBC Future: Why is there no universal flu vaccine? (news report)<\/a><\/li>\n<li><a href=\"https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/epidemic-and-pandemic-threats\" target=\"_blank\" rel=\"noopener\">World Health Organization: Epidemic and Pandemic Threats Management (official)<\/a><\/li>\n<li><a href=\"https:\/\/icahn.mssm.edu\/profiles\/florian-krammer\" target=\"_blank\" rel=\"noopener\">Icahn School of Medicine: Florian Krammer profile (academic)<\/a><\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Lead Researchers worldwide are pursuing vaccines that protect against many influenza strains, not just one season&#8217;s variants. Each year roughly 1 billion people become infected and between 290,000 and 650,000 die from influenza-related causes, driving urgency for longer\u2011lasting, broader protection. Teams at institutions including Duke, Mount Sinai and Stanford report promising laboratory and early clinical &#8230; <a title=\"Universal flu vaccine: How scientists are closing in on the viruses &#8216;weak spots&#8217; &#8211; BBC\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/universal-flu-weak-spots\/\" aria-label=\"Read more about Universal flu vaccine: How scientists are closing in on the viruses &#8216;weak spots&#8217; &#8211; BBC\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":21988,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Universal flu vaccine: closing in on viral weak spots | DeepNews","rank_math_description":"Scientists are developing broadly protective flu vaccines by targeting conserved viral components. Early trials and new methods show promise, but a universal shot remains years away.","rank_math_focus_keyword":"universal flu vaccine, haemagglutinin, neuraminidase, broad protection","footnotes":""},"categories":[2],"tags":[],"class_list":["post-21992","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/21992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=21992"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/21992\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/21988"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=21992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=21992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=21992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}